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Introduction: In early sepsis stages, optimal treatment could contribute to prevention of progression to severe
sepsis. Therefore, we investigated if there was an association between time to antibiotics and relevant clinical
outcomes in hospitalized emergency department (ED) patients with mild to severe sepsis stages.
Methods: This is a prospective multicenter study in three Dutch EDs. Patients were stratified into three categories
of illness severity, as assessed by the predisposition, infection, response, and organ failure (PIRO) score: PIRO score 1
to 7, 8 to 14 and >14 points, reflected low, intermediate, and high illness severity, respectively. Consecutive hospitalized
ED patients with a suspected infection who were treated with intravenous antibiotics were eligible to participate in the
study. The primary outcome measure was the number of surviving days outside the hospital at day 28 which was used as
an inverse measure of hospital length of stay (LOS). The secondary outcome measure was 28-day mortality, taking into
account the time to mortality.
Multivariable Cox regression analysis was used to estimate the association between time to antibiotics and the
primary and secondary outcome measures corrected for confounders, including appropriateness of antibiotics and
initial ED resuscitation, in three categories of illness severity.
Results: Of the 1,168 included patients, 112 died (10%), while 85% and 95% received antibiotics within three and six
hours, respectively. No association between time to antibiotics and surviving days outside the hospital or mortality
was found. Only in PIRO group 1 to 7 was delayed administration of antibiotics (>3 hours) associated with an increase
in surviving days outside the hospital at day 28 (hazard ratio: 1.46, 95% confidence interval: 1.05 to 2.02 after correction
for potential confounders).
Conclusions: In ED patients with mild to severe sepsis who received antibiotics within six hours after ED presentation,
a reduction in time to antibiotics was not found to be associated with an improvement in relevant clinical outcomes.Introduction
The association between time to antibiotics and relevant
clinical outcomes has been extensively studied [1-9], es-
pecially in patients with severe sepsis and septic shock
admitted to the intensive care unit (ICU). In three large
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gency department (ED) patients [10]. However, in one
prospective study with excellent control for quality of
hemodynamic resuscitation and a relatively low mortal-
ity of 19%, time to antibiotics was not found to be asso-
ciated with mortality in septic shock patients, suggesting
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ministration of antibiotics before the onset of shock was
associated with improved outcome [11]. The impact of
early administration has never been studied prospect-
ively in earlier sepsis stages, that is, before the onset of
acute organ failure. In these patients progression to severe
sepsis, which occurs in approximately 22% [12], could
still be prevented and hemodynamic resuscitation is less
important.
In addition to the association with mortality, several
retrospective studies have suggested that early adminis-
tration of antibiotics reduces hospital lengths of stay
(LOS), potentially having an enormous impact on hospital
finances and patient comfort and satisfaction [1,2,13,14].
However, the retrospective design of these studies made
them prone to information bias, especially in the measure-
ment of time to antibiotics, and limited the possibility to
control for the potential confounding effect of quality of
initial resuscitation. Furthermore, LOS has important in-
teractions with mortality. For example, it may well be that
most severely ill patients received antibiotics early. In
these patients, hospital LOS may well be decreased due to
early mortality, and not by beneficial effects of early ad-
ministration of antibiotics.
Importance
Presently, no studies have prospectively investigated the
association between time to antibiotics and relevant out-
comes in earlier sepsis stages. Given the high incidence
of ED patients with uncomplicated sepsis who have a
substantial chance to progress to severe sepsis [12],
and the financial burden associated with severe sepsis
[15,16], it would be important to explore if a measure
as simple as early administration of antibiotics decreases
hospital LOS, and thereby contributes to a reduction in
healthcare-related costs [17].
Goals of this investigation
The purpose of the present study was to prospectively
study the association between time to antibiotics and
hospital LOS and 28-day mortality in ED patients with a
suspected infection, in three categories of disease severity,
taking into account the quality of initial ED treatment (in-
cluding appropriateness of antibiotics and hemodynamic
resuscitation) and the confounding effect of mortality on
hospital LOS.
Methods
Study design and setting
This was a prospective observational cohort study con-
ducted in the EDs of three Dutch hospitals: the Leiden
University Medical Center (LUMC; approximately 30,000
visits/year), the Rijnstate hospital (RH; an urban hos-
pital with approximately 30,000 visits/year), and the VUUniversity Medical Center (VUMC; approximately 30,000
visits/year). Patients were included from 1 June 2011 to 1
April 2013 in the LUMC, from 1 March 2012 to 1 April
2013 in the RH, and from 1 April 2012 to 1 April 2013 in
the VUMC.
The study was approved by the medical ethics committee
of the Leiden University Medical Center, who waived the
need for individual informed consent as this was a purely
observational study (P 12.014). In the Netherlands, approval
of one ethical body is enough to perform a study in
multiple centers.
Selection of participants
All consecutive ED patients aged 17 years and older, with
suspected infection and triage category (Manchester triage
system, [18]) yellow, orange, or red, who were admitted to
the hospital and treated with intravenous antibiotics were
included by the triage nurse or the nurse or physician who
took care of the patient. Triage categories blue and green
were excluded because most of these patients were ex-
pected to be at very low risk for mortality or hospital ad-
mission (for example patients with a simple pharyngitis).
Any sign that triggered the triage nurse and treating phys-
ician to suspect an infection was suitable (fever, coughing,
erythema, and so forth). Patients who appeared to have no
infection according to their final hospital discharge letter
were excluded (for example, those with pulmonary em-
bolus or auto-immune and hematologic disorders present-
ing with fever).
Data collection
In all participating hospitals, the same SSC-based quality
improvement program was used, in which a standard
screening procedure was followed to optimize sepsis rec-
ognition and early ED resuscitation and disposition to
an adequate level of care (see Additional file 1): the triage
or treating nurse put a patient sticker on a registration
form if a patient had a suspected infection and triage cat-
egory yellow, orange, or red. All nurses and/or physicians
were informed about the data that had to be collected by
means of oral presentations, posters, and flyers in the
ED, and the registration form which contained the study
protocol. Demographic and comorbidity data, relevant
time points and dates, laboratory variables, triage categor-
ies and vital signs, type of antibiotics, amount and type of
fluids (L), administered oxygen (L/min), disposition, and
outcome variables were prospectively registered in the
digital hospital information system Chipsoft Ezis (Chipsoft,
Amsterdam, Netherlands) of each participating hospital. A
medical student or registrar in emergency medicine subse-
quently transferred data from the electronic hospital infor-
mation system to a web-based data collection file that was
specifically developed for the present study (PromiseBasic,
Leiden, Netherlands), and which automatically calculated
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of surviving days outside the hospital at 28 days after ED
presentation. After the inclusion period, data of the three
participating hospitals were transferred to one SPSS file
(SPSS version 20.0, IBM, New York, USA).
Illness severity was assessed by the initial predispos-
ition, infection, response, and organ failure (PIRO) score,
which has been specifically developed and validated for
the ED population as described in this study [19], and
has also been validated for the Dutch ED setting [20].
The PIRO scores were calculated retrospectively so that
the treating physicians were not aware of the score at
the time of ED presentation. Missing values were counted
as normal in the calculations of the PIRO score, similar as
in the acute physiology and chronic health evaluation
(APACHE) score [21]. A patient was considered to have a
‘do not resuscitate’ (DNR) status if the existing medical
files already stated that the patient had a DNR code, or if
it was decided at the time of ED presentation or during
hospital admission.
Time to antibiotics was measured by subtraction of
registration time at the ED desk from the registered time
of antibiotic administration by the nurse. To test the ac-
curacy of the registration of the time of antibiotic ad-
ministration, the registered time was compared to the
observed time of antibiotic administration in 53 included
patients in the three hospitals in the following way: one
of the doctors in the participating institutions was asked
to register the exact time at which the antibiotics were
administered to the ED patient on the registration form.
Nurses were not informed about this procedure. After
the inclusion period was finished, the observed start
time of administration of the first antibiotics was com-
pared to the registered time of antibiotic administration
(see Additional file 2). Time as zero was taken as the
time at ED registration.
The appropriateness of the initial dose of antibiotics
administered in the ED was assessed in retrospect as is
summarized in Additional file 3. In culture-positive pa-
tients, initial antibiotics were considered to be appropri-
ate if the cultured microorganism could be a causative
pathogen in relation to the clinical findings, and showed
in-vitro sensitivity for the initial dose of the antimicro-
bial agent. Staphylococcus epidermidis, Staphylococcus
hominis, and other coagulase negative staphylococci were
considered to be contaminates (and therefore analyzed as
if culture-negative), except in cases with endocarditis or
infections caused by foreign bodies such as prostheses. An
infectious disease specialist helped to evaluate and inter-
pret the microbiological data. Culture-negative patients
were also included in the analysis because for the ED phys-
ician it is unknown at time of presentation if cultures
will become positive, and these patients might have had
an infection.In culture-negative patients, the initial antibiotics pre-
scribed in the ED were considered to have been effective
when patients recovered without the need to change to
other antibiotics because the patient clinically deterio-
rated. If patients died during hospital admission, antibi-
otics were considered to have been effective if the initial
antibiotics were administered according to institutional
protocol for antibiotic therapy for specific infections.Outcome measures
The primary outcome measure was the number of surviv-
ing days outside the hospital at day 28 after ED presenta-
tion. For example, if a patient would have been discharged
alive after five days hospital admission, the number of sur-
viving days outside the hospital would be 23 days. If the
patient would have died in the hospital after five days of
admission, the number of surviving days outside the hos-
pital would be zero.
In this way the potential confounding effect of hospital
mortality on hospital LOS is prevented. For example, if
delayed treatment with antibiotics would result in pro-
longed hospital stay, this effect could be masked by in-
creased early mortality. The endpoint ‘surviving days
outside the hospital at day 28’ is analogous to the often
used endpoint ‘ventilator free days at day 28’ in studies in
ICU patients [22].
A secondary outcome measure was survival time up to
28 days after initial ED presentation. Patients were fol-
lowed up on until 28 days after the initial ED presentation.
Patients who were discharged from the hospital within 28
days were contacted by telephone to find out their survival
status at 28 days.Data analysis
Data were presented as mean (SD) if normally distributed,
and median (interquartile range (IQR)) if skewed. Cox
regression analysis was used to assess the association
between time to antibiotics and number of surviving days
outside the hospital at day 28 because this is a non-
parametric modeling method, requiring few assumptions
about linearity, normality, or censored data.
It has been reported that treatment benefits may in-
crease with illness severity, while others have suggested
that only patients with intermediate illness severity
benefit, meaning that patients with low or high disease
severity will survive or die, respectively, regardless of the
provided treatment; some therapies may even be harm-
ful in low risk populations [23-25]. Because of the many
potential confounders and interactions, we chose to do
the analyses in three separate groups with low (PIRO
score 1 to 7), moderate (PIRO score 8 to 14), or high ini-
tial illness severity (PIRO score >14), rather than adding
interaction terms in the model, because this requires less
de Groot et al. Critical Care  (2015) 19:194 Page 4 of 12assumptions. Within each PIRO category, adjustment by
PIRO score was performed.
Time to antibiotics was divided into three categories
because the association between time to antibiotics and
outcome was not expected to be linear, based on the
combination of observations in previous studies [7-9].
Categories were administration within one hour, between
one and three hours, and after three hours, because
these categories were considered most relevant for the
ED setting.
An association model [26], as opposed to a prediction
model, was constructed per PIRO group to describe the
association between time to antibiotics and outcome as
accurate as possible. First, each of the following prede-
fined potential confounders were added separately into
the starting model with time to antibiotics and outcome:
patient variables (the separate P, I, R, and O scores) in
addition to the use of antibiotics, statins, or β-blockers
prior to ED presentation, because previous studies showed
that these might affect outcome [1,27-29]; ED treatment
variables (amount of fluids, oxygen, and appropriateness
initial antibiotics); and disposition to ward or ICU (or
medium care unit (MCU)). The participating hospital was
also put in the model as a separate variable to correct for
structural differences among participating hospitals. The
variable that resulted in the largest change of the regres-
sion coefficient of the association between the time to an-
tibiotics and outcome was then added to the model,
which subsequently became the new starting model. This
procedure was repeated until addition of a new predefined
potential confounder resulted in a change of the regres-
sion coefficient of the primary association of interest of
less than 10%, which was no longer considered relevant.
Hazard ratios ((HR) and 95% confidence intervals (CI)
for the association between time to antibiotics (antibi-
otics within one hour was set as the reference) and out-
comes were calculated and reported for the crude and
corrected models. Although not the explicit purpose of
the present study, HRs of the confounders of the cor-
rected models were also reported because these could help
in generating hypothesis for future studies. The P values
of these confounders were therefore reported, but were
not used to construct the model. All data were analyzed
using SPSS software (SPSS 20.0, IBM, New York, USA).
Sensitivity analysis
Because the appropriateness of antibiotics, the absence
of a positive culture, and DNR status could have an im-
portant effect on the primary association of interest, a
sensitivity analyses were performed. First, the aforemen-
tioned analysis was performed in patients who received
appropriate and inappropriate antibiotics in two separate
models. Second, the same analysis was performed with
and without forced entry of DNR status. Third, the sameanalysis was performed only in culture-positive patients.
Fourth, we also performed the analysis with forced entry
of all potential predefined variables, to be sure that the
model was not affected by the stepwise procedure itself.
Sample size calculations
For the outcome ‘number of surviving days outside the
hospital at day 28 after ED presentation’, the present
study had a power of 80%, calculated a priori to detect a
difference in outcome (α = 0.05) of one day between a
group with time to antibiotics below or above the median
time to antibiotics. The expected number of surviving
days outside the hospital at day 28 was 23, and was de-
rived from the study of Houck et al. [1]. In this calcula-
tion, the skewed distribution of the number of surviving
days outside the hospital was taken into account. It was
calculated that approximately 400 inclusions per PIRO
category were needed. The rule of thumb that approxi-
mately 10 events per potential confounder was needed for
sufficient power was taken into account, in order to set
the number of confounders that could be adjusted for in
the analysis, with 28-day mortality as outcome measure.
Results
Patient characteristics and inclusion
Figure 1 shows a diagram of patient inclusion and flow
through the study. A total of 1,168 patients were included:
413 patients in PIRO category 1 to 7, 532 patients in PIRO
category 8 to 14, and 223 patients in PIRO category >14.
Patient characteristics are shown in Table 1 as a function
of illness severity. Time to antibiotics decreased with
increasing PIRO category. However, within one PIRO cat-
egory there was no association between PIRO score and
time to antibiotics (minutes); regression coefficients (CI)
for linear regression were −12.38 (−35.05 to 10.30) for
PIRO 1 to 7, −10.21 (−25.90 to 5.48) for PIRO 8 to 14 and
8.44 (−12.36 to 29.25) for PIRO >14.
A total of 85% and 95% of the patients received antibi-
otics within three and six hours, respectively. The accur-
acy of registration of time to antibiotics is shown in
Additional file 2. Excellent correlation was found between
the registered time to antibiotics and time to antibiotics
by an independent observer (N = 53, r2: 0.926, regression
coefficient (SEM): 0.98 (0.04), constant: −0.72 minutes).
Overall 28-day mortality in the present cohort was 10%,
ranging from 2% in PIRO group 1 to 7 to 23% in PIRO
group >14.
Association between time to antibiotics and relevant
clinical outcomes
The association between time to antibiotics with poten-
tial confounders, and surviving days outside the hospital
at day 28 (primary endpoint) and 28-days mortality is
shown in Tables 2 and 3.
Figure 1 Patient inclusion and flow through study. Illness severity was expressed as Predisposition, Infection, Response, and Organ failure
(PIRO) score.
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hour was set as reference category to which the other
two categories were compared. For example, a HR larger
than 1 in the category ‘time to antibiotics >3 hours’ indi-
cates that administration of antibiotics after three hours
is associated with a larger number of surviving days out-
side the hospital at day 28 (In Table 2), or a larger hazard
for mortality (in Table 3). An HR below 1 indicates the
opposite. In the present cohort with relatively low mortal-
ity and a small range of time to antibiotics, a reduction in
time to antibiotics was not found to be significantly asso-
ciated with an improvement of relevant clinical outcomes,
that is, the HRs were not significantly different from 1.
However, for the PIRO category with lowest illness sever-
ity (1 to 7), time to antibiotics under three hours was asso-
ciated with a larger number of surviving days outside the
hospital at day 28 after ED presentation. No association
was found between time to antibiotics and survival time
censored at 28 days, irrespective of severity of illness by
PIRO category.
In Table 4 the relevant treatment aspects and out-
comes per PIRO category were shown as a function of
the three categories of time to antibiotics. It can be seen
that the percentage of appropriateness of antibiotics is
not higher in the group with administration of antibi-
otics after three hours. In addition, the relevant clinical
outcomes are also similar among time to antibiotics
categories.
Although the present study did not aim to test if there
were other potential predictors of relevant clinical out-
comes, the associations between the confounders of theprimary association of interest and the primary and sec-
ondary outcome measures were shown in Tables 2 and 3
because they may explain the lack of a significant associ-
ation between time to antibiotics and relevant clinical
outcomes. Other aspects of ED treatment, such as the
amount of administered oxygen and fluids and the ap-
propriateness of the initial dose of antibiotics adminis-
tered in the ED, were associated with relevant clinical
outcomes which may provide important directives for
future studies.
Sensitivity analyses
First, the analyses were performed separately in ED
patients who received appropriate and inappropriate an-
tibiotics to investigate if the primary association of inter-
est was different: the corrected HRs for surviving days
outside the hospital at day 28 (antibiotics within one
hour was set as reference) for the group who received
appropriate antibiotics (n = 899) were 1.58 (95% CI:
0.865 to 2.87, P = 0.137) and 1.43 (95% CI: 0.614 to 3.34,
P = 0.406) for patients who received antibiotics between
one and three and after three hours, respectively. For pa-
tients who received inappropriate antibiotics (n = 258)
the corrected HRs were 0.96 (95% CI: 0.48 to 1.91) and
0.31 (95% CI: 0.068 to 1.46). Analysis in the three separ-
ate PIRO groups yielded similar results. Similarly, ana-
lyses in only patients with positive cultures (n = 651) did
not change the primary association of interest (data not
shown). Furthermore, forced entry of all potential pre-
dictor variables to the model did not change the primary
association of interest.
Table 1 Patient characteristics as a function of illness severity as indicated by PIRO category
Total cohort (n = 1,168) PIRO 1 to 7 (n = 413) PIRO 8 to 14 (n = 532) PIRO >14 (n = 223)
Demographics
Age, mean (SD) 62 (17) 54 (16) 64 (17) 72 (14)
Male sex (%) 650 (56) 211 ((51) 295 (55) 144 (65)
Comorbidities, n (%)
COPD 191 (16) 23 (6) 101 (19) 67 (30)
Heart disease 104 (9) 24 (6) 51 (10) 29 (13)
Liver disease (1) 42 (4) 11 (3) 13 (2) 18 (13)
Renal disease (1) 172 (15) 55 (13) 72 (14) 45 (20)
Malignancy− 137 (12) 41 (10) 57 (11) 39 (17)
Malignancy+ (2) 131 (11) 32 (8) 63 (12) 36 (16)
Immune-compromised (1) 410 (35) 159 (38) 163 (31) 88 (39)
Nursing home (1) 79 (7) 4 (1) 29 (5) 46 (21)
DNR status (6) 277 (24) 40 (10) 133 (25) 104 (47)
Medication use at ED presentation, n (%)
β-Blocker/Ca-antagonist (13) 348 (30) 103 (25) 169 (32) 76 (34)
Statins (11) 284 (33) 81 (20) 142 (27) 61 (27)
Antibiotic use (10) 306 (26) 99 (24) 138 (26) 69 (69)
Vital signs at ED presentation, mean (SD)
Respiratory rate (per minute) (373) 26 (8) 18 (4) 27 (7) 30 (8)
Oxygen saturation (%) (60) 95 (5) 97 (3) 94 (6) 93 (6)
Heart rate (per minute) (40) 109 (20) 105 (18) 109 (20) 116 (23)
Systolic BP (mmHg) (186) 133 (27) 130 (24) 137 (27) 129 (30)
Diastolic BP (mmHg) (187) 76 (17) 75 (15) 77 (17) 72 (19)
Temperature (°C) (32) 38.7 (2.3) 38.6 (1.8) 38.9 (2.8) 38.7 (1.2)
Altered mental status 208 (18) 40 (10) 100 (19) 68 (30)
Febrile chills 278 (24) 126 (31) 114 (21) 38 (17)
Laboratory, median (IQR)
Lactate (mmol/L) (202) 1.8 (1.3-2.5) 1.6 (1.2-2.1) 1.7 (1.3-2.4) 2.2 (1.6-4.0)
Creatinine (μmol/L) (9) 87 (66–118) 81 (65–102) 83 (64–116) 110 (82–156)
Urea (mmol/L) (31) 6.8 (5–10.1) 5.6 (4.4-7.6) 6.8 (5.0-9.9) 10 (7.7-14.4)
Platelets (1012/mm3) (24) 210 (155–282) 209 (164–279) 218 (163–287) 182 (117–270)
Bilirubin (μmol/L) (404) 12 (8–18) 12 (9–18) 12 (8–18) 13 (9–24)
Suspected site of infection, n (%)
Lung 617 (513 105 (25) 326 (61) 186 (83)
UTI 335 (29) 113 (27) 145 (27) 77 (35)
Abdominal 199 (17) 89 (22) 83 (16) 27 (12)
Skin 97 (8) 63 (15) 27 (5) 7 (3)
Neurological 33 (3) 10 (1) 16 (3) 7 (3)
Other 192 (16) 86 (21) 86 (16) 20 (9)
Data are presented as mean (SD) if normally distributed, or as median (IQR) if rightly skewed. Categorical data are presented as number (%). Percentages of
suspected sites of infection do not add up to a 100% because some patients had multiple suspected sites of infection at the time of ED presentation. Missing
values are shown in bold between brackets for every variable.
BP, blood pressure; COPD, chronic obstructive pulmonary disease; DNR status, do not resuscitate status; ED, emergency department; IQR, interquartile range;
Malignancy−, malignancy without metastases; Malignancy+, malignancy with metastases and hematologic malignancy; MV, missing value; PIRO, Predisposition,
Infection, Response, and Organ failure score; SD, standard deviation; UTI, urinary tract infection.
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Table 2 Number of surviving days outside the hospital at day 28 as a function of time to antibiotics in ED patients
with a suspected infection in three categories of illness severity
Crude model HR (95% CI) Corrected model HR (95% CI) P (Corrected model)
PIRO group 1 to 7
Antibiotics <1 hour (reference category) 1 1 0.02a
Antibiotics 1–3 hours 0.84 (0.66-1.06) 1.03 (0.78-1.36) 0.824
Antibiotics >3 hours 1.11 (0.84-1.46) 1.46 (1.05-2.02) 0.023
Type of hospital (academic versus urban) 0.635 (0.486-0.831) 0.001
P score 1.16 (1.04-1.30) 0.008
O score 1.03 (0.96-1.12) 0.408
Statin use 1.32 (1.02-1.70) 0.033
Appropriateness of antibiotics 0.61 (0.46-0.81) 0.001
Amount of oxygen (L/min) 1.01 (0.99-1.04) 0.301
Amount of fluids (L/ED stay) 1.23 (1.06-1.43) 0.005
PIRO group 8 to 14
Antibiotics <1 hour (reference category) 1 1 0.984a
Antibiotics 1–3 hours 0.85 (0.70-1.02) 1.02 (0.83-1.25) 0.863
Antibiotics >3 hours 0.79 (0.60-1.04) 1.02 (0.75-1.38) 0.910
Type of hospital (academic versus urban) 0.54 (0.44-0.66) <0.001
P score 1.05 (1.00-1.11) 0.05
O score 1.06 (1.00-1.13) 0.037
Appropriateness of antibiotics 0.76 (0.61-0.93) 0.008
Amount of oxygen (L/min) 1.02 (1.00-1.04) 0.015
Amount of fluids (L/ED stay) 1.03 (0.92-1.16 0.616
PIRO group >14
Antibiotics <1 hour (reference category) 1 1 0.361a
Antibiotics 1–3 hours 1.00 (0.75-1.32) 1.16 (0.86-1.58) 0.366
Antibiotics >3 hours 0.89 (0.57-1.40) 1.40 (0.84-2.34) 0.194
Type of hospital (academic versus urban) 0.69 (0.50-0.96) 0.025
P score 1.10 (1.00-1.22) 0.041
O score 1.09 (1.02-1.17) 0.017
Statin use 0.84 (0.61-1.15) 0.277
Antibiotics use 1.04 (0.77-1.41) 0.789
Appropriateness of antibiotics 0.70 (0.51-0.95) 0.024
Amount of oxygen (L/min) 1.03 (1.01-1.05) 0.014
Amount of fluids (L/ED stay) 1.14 (1.01-1.29) 0.042
Cox regression analysis was performed with time to antibiotics divided into three categories, corrected for possible predefined confounders: PIRO score; antibiotic,
β-blocker, or statin use prior to ED presentation; efficacy of antibiotics; amount of fluids (L); amount of oxygen (L/min) in the ED; and type of hospital (academic
versus urban hospital). Hazard ratio >1 indicates a larger number of days outside the hospital at day 28 after ED presentation compared to the reference category
of time to antibiotics within one hour. aOverall P value for categories of time to antibiotics. The P values were not used to construct the model.
CI, Confidence interval; ED, Emergency department; HR, Hazard ratio; ICU, Intensive care unit; and PIRO, Predisposition, Infection, Response, and Organ failure
score (as a measure of illness severity).
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The main new finding of the present study is that a reduc-
tion in time to antibiotics was not found to be associated
with an improvement of relevant clinical outcomes in our
cohort of ED patients with mild to severe stages of sepsis.
A reduction in time to antibiotics was also not found to be
associated with an increase in number of surviving daysoutside the hospital at day 28 after ED presentation. Corre-
sponding to the number of ventilator-free days in ICU-
related studies [22], we chose this primary endpoint instead
of hospital LOS to avoid confounding of the association
between time to antibiotics and hospital LOS by mortality.
Our findings are in contrast to a study by Houck et al.
of approximately 14,000 patients with a pneumonia, which
Table 3 The hazard for 28-day mortality as a function of time to antibiotics in ED patients with suspected infection in
three categories of illness severity
Crude model (HR (95% CI) Corrected model (HR (95% CI) P (Corrected model)
PIRO group 1 to 7 (n = 413)
Antibiotics <1 hour (reference category) 1 1 0.422a
Antibiotics 1–3 hours 0.95 (0.17-5.18) 2.55 (0.36-18.25) 0.352
Antibiotics >3 hours 1.98 (0.36-10.78) 5.31 (0.43-68.16) 0.191
Type of hospital (academic versus urban) 0.06 (0.007-0.48) 0.008
P score 2.53 (1.41-4.56) 0.002
Appropriateness of antibiotics 0.33 (0.06-1.66) 0.180
Amount of oxygen (L/min) 1.17 (1.02-1.35) 0.028
Amount of fluids (L/ ED stay) 1.65 (0.76-3.59) 0.205
PIRO group 8 to 14 (n = 532)
Antibiotics <1 hour (reference category) 1 1 0.676a
Antibiotics 1–3 hours 1.11 (0.62-1.99) 1.25 (0.62-2.31) 0.488
Antibiotics >3 hours 0.65 (0.22-1.90) 0.86 (0.28-2.63) 0.786
Type of hospital (academic versus urban) 0.35 (0.19-0.68) 0.002
P score 1.29 (1.14-1.46) <0.001
R score 0.74 (0.62-0.89) 0.001
O score 1.28 (1.10-1.50) 0.002
Amount of oxygen (L/min) 1.04 (1.00-1.09) 0.067
PIRO group >14 (n = 223)
Antibiotics <1 hour (reference category) 1 1 0.978a
Antibiotics 1–3 hours 1.10 (0.62-1.97) 0.99 (0.53-1.87) 0.983
Antibiotics >3 hours 0.93 (0.36-2.43) 1.11 (0.40-3.08) 0.849
Type of hospital (academic versus urban) 1.57 (0.83-3.00) 0.166
O score 1.15 (1.00-1.34) 0.056
β-blocker use 0.96 (0.51-1.79) 0.892
Appropriateness of antibiotics 0.35 (0.19-0.62) <0.001
Amount of oxygen (L/min) 1.01 (0.98-1.04) 0.414
Amount of fluids (L/ED stay) 0.88 (0.65-1.20) 0.425
Cox regression analysis was performed with time to antibiotics divided into three categories. In the corrected model regression coefficients were corrected for
possible predefined confounders: PIRO score; β-blocker, statin, and antibiotic use prior to ED presentation; appropriateness of initial antibiotics in the ED; amount
of fluids (L); amount of oxygen (L/min) in the ED; and hospital (academic versus urban hospital). aOverall P value for categories of time to antibiotics. The P values
were not used to construct the model.
CI, Confidence interval; ED, Emergency department; HR, Hazard ratio; ICU, Intensive care unit; PIRO, Predisposition, Infection, Response, and Organ failure score
(as a measure of illness severity).
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istration of antibiotics after four hours [1]. Several differ-
ences may explain the discrepancy. The retrospective
design of the study is prone to information bias, especially
with regard to the timing of antibiotics. Furthermore, it
consisted of a population with only elderly patients with
pneumonia, while in our study all adults with all sources
of infection were included. Also, there was no control for
appropriateness of the initial choice of antibiotics and
amount of fluids. Several smaller retrospective studies that
found an increased hospital LOS with administration of
antibiotics beyond two to eight hours had similar meth-
odological drawbacks [13,14].Unexpectedly, we found that in the PIRO 1 to 7 group,
administration of antibiotics after three hours was sig-
nificantly associated with a larger number of surviving
days outside the hospital. It is unlikely that delaying
antibiotic treatment is beneficial for patients with infec-
tions. The most likely explanation for the unexpected
association of delayed administration of antibiotics with
shorter hospital stay is that administration of antibiotics
is more often delayed in patients with less severe infec-
tions. In contrast, severely ill patients may be adminis-
tered antibiotics shortly after admission to the ED. This
confounding effect of severity of illness may not be com-
pletely adjusted for by including the PIRO score in the
Table 4 Treatment variables and relevant clinical outcomes per PIRO category as a function of timing of antibiotics
Antibiotics <1 hour
(reference category)
Antibiotics 1–3 hours Antibiotics >3 hours
PIRO 1 to 7 (N = 413) n = 101 n = 211 n = 101
ED treatment
Number of SSC goals achieved, mean (SD) (9) 3.3 (1.0) 3.7 (0.9) 2.7 (0.9)
Time to antibiotics (minutes), median (IQR) (1) 41 (32–51) 110 (85–141) 295 (216–516)
Initial antibiotics appropriate, n (%) (11) 84 (84) 182 (86) 73 (72)
Administered fluids (L), median (IQR) 1.0 (0.5-1.5) 1.0 (0.5-1.5) 0.5 (0.5-1.0)
Administered oxygen (L/min), median (IQR) (53) 2.0 (0.0-3.0) 0 (0.0-3.0) 0 (0.0-3.8)
Disposition/outcomes
MCU/ICU admission, n (%) (18) 7 (7) 7 (209) 2 (2)
Total hospital LOS (days), median (IQR) 5 (3–8) 4 (2–8) 6 (3–12)
Number of surviving days outside hospital at day 28, median (IQR) 23 (20–25) 23 (19–26) 21 (15–25)
28-day mortality, n (%) (7) 2 (2) 4 (2) 4 (2)
PIRO 8 to 14 (N = 532) n = 217 n = 249 n = 66
ED treatment
Number of SSC goals achieved, mean (SD) (9) 3.7 (1.1) 3.7 (0.9) 3.0 (0.9)
Time to antibiotics (minutes), median (IQR) (1) 38 (24–48) 102 (78–133) 243 (201–367)
Initial antibiotics appropriate, n (%) (11) 166 (76) 183 (73) 50 (76)
Administered fluids (L), median (IQR) 1.0 (0.5-1.6) 1.0 (0.5-1.5) 1.0 (0.5-1.5)
Administered oxygen (L/min), median (IQR) (53) 2.0 (1.0-5.0) 3.0 (0.0-5.0) 3.0 (0.0-5.0)
Disposition/outcomes
MCU/ICU admission, n (%) (18) 29 (13.4) 23 (9) 2 (3)
Total hospital LOS (days), median (IQR) 6 (4–10) 6 (3–9) 5 (3–9)
Number of surviving days outside hospital at day 28, median (IQR) 21 (15–24) 22 (14–24) 22 (18–25)
28-day mortality, n (%) (7) 20 (3) 26 (10) 4 (6)
PIRO >14 (N = 223) n = 113 n = 87 n = 23
ED treatment
Number of SSC goals achieved, mean (SD) (9) 4.0 (1.1) 3.8 (1.0) 3.0 (0.7)
Time to antibiotics (minutes), median (IQR) (1) 33 (23–33) 95 (81–126) 295 (218–499)
Initial antibiotics appropriate, n (%) (11) 81 (74) 61 (70) 18 (78)
Administered fluids (L), median (IQR) 1.0 (0.5-2.0) 1.0 (0.5-1.6) 0.6 (0.5-1.5)
Administered oxygen (L/min), median (IQR) (53) 5.0 (2.0-10.0) 3.0 (2.0-10.0) 3.0 (1.5-5.0)
Disposition/outcomes
MCU/ICU admission (18) 33 (29) 15 (17) 4 (17)
Total hospital LOS (days), median (IQR) 7 (5–13) 8 (3–12) 7 (3–8)
Number of surviving days outside hospital at day 28, median (IQR) 18 (0–22) 17 (4–22) 20 (3–23)
28-day mortality, n (%) (7) 26 (23) 21 (24) 5 (22)
Data are presented as mean (SD) if normally distributed or as median (IQR) if rightly skewed. Categorical data are presented as number (%). Missing values are
shown in bold between brackets for every variable.
ED, Emergency Department; ICU, Intensive Care Unit; IQR, interquartile range; LOS, Length of Stay; MCU, Medium Care Unit; PIRO, Predisposition, Infection,
Response, and Organ failure; SD, standard deviation; SSC, Surviving Sepsis Campaign.
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range (PIRO 1 to 7) the PIRO score has limited discrim-
inative value, as shown in the study by Howell et al.
[19]. In contrast to the study by Hranjec et al. in surgical
ICU patients [30], the percentage of patients who receivedappropriate antibiotics in the ED was lower in the group
with delayed administration of antibiotics. This could
therefore not explain the association of delayed adminis-
tration of antibiotics and the larger number of surviving
days outside the hospital in PIRO category 1 to 7. Finally,
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est did not change, but the aforementioned unexpected
finding was no longer significant. It cannot be excluded,
however, that unknown confounders may be responsible
for this unexpected finding.
In this prospective study in ED patients, a reduction in
time to antibiotics was not found to be associated with a
reduction in mortality. The most likely explanation for
the discrepancy with the three large retrospective studies
that showed that delayed administration of antibiotics is
associated with increased mortality is the much lower
overall mortality, that is, disease severity, in the present
study. This suggests that, in less severely ill patients,
timing of antibiotics is less important than other aspects
of ED treatment, including appropriateness of antibiotics
and initial resuscitation with fluids and oxygen. Al-
though it should be emphasized that the present study
was not designed to estimate the effect of other treat-
ment variables on relevant clinical outcomes, it should
be noted that several confounders of the primary associ-
ation of interest, such as appropriateness of antibiotics,
supplemental oxygen, and fluids, were significantly asso-
ciated with the clinical endpoints of the present study.
Interestingly, appropriateness of initially administered
antibiotics was associated with lower mortality, but pos-
sibly at the expense of less surviving days outside the hos-
pital. It may be hypothesized that these variables represent
more important aspects of ED treatment compared to
time to antibiotics, at least in study cohorts with relatively
low mortality. Correspondingly, in a study by Rivers et al.,
early goal-directed therapy (EGDT) had an enormous im-
pact on outcome in a study cohort with 47% mortality
[31], while the ProCESS trial (Protocol-based Care for
Early Septic Shock) showed no benefit of EGDT in a study
cohort with a much lower mortality of around 20% [32],
which is in line with the previous observations that treat-
ment benefits depend on disease severity. Indeed, some
effective therapies were shown to be less relevant or even
harmful in low risk populations [23-25].
Study strengths and weaknesses
The strengths of the present study include the prospective
design, the adjustment for illness severity, the quantification
of the accuracy of the registration of time to antibiotics,
and excellent control for predefined potential confounders,
including ED treatment and relevant medication. How-
ever, there are also some limitations.
First, in the most severely ill group (PIRO >14), there
were fewer than 400 patients, therefore the power in this
group might be relatively low. However, although we
wanted to explicitly investigate the effect of illness severity
on the association between time to antibiotics and rele-
vant outcomes, in retrospect the illness severity (PIRO
category) did not affect the association. Therefore, we alsoinvestigated all 1,168 included patients in a model with
PIRO score as an interaction term with time to antibiotics
in SPSS. In this model, the interaction term was not sig-
nificant (P = 0.209), indicating that in retrospect we in-
deed could have analyzed all patients in one group. After
having performed this analysis the main conclusion of the
study still stands: no association between time to antibi-
otics and relevant clinical outcomes was found. In this
analysis approximately three times more patients were an-
alyzed than needed (a priori calculated sample size of
400). It is therefore unlikely that the absence of an associ-
ation is attributed to limited power of the study. The rela-
tively small number of deaths (secondary outcome) in
PIRO group 1 to 7 may have resulted in less accurate
effect size estimations. The HRs in this group with
very mild disease severity should therefore be interpreted
with caution.
Second, because many patients had negative cultures,
the estimation of appropriateness of the initial choice of
antibiotics may include inaccuracies. We believe, how-
ever, that the predefined flow diagram to decide if an
antimicrobial agent was appropriate was the most ob-
jective way in culture-negative patients. Furthermore,
similar strategies to interpret appropriateness of antibi-
otics were used in the most relevant previous studies
[7-9,11], facilitating comparison of our results with those
found in the literature. In addition, a realistic association
between efficacy of antibiotics and relevant endpoints is
also obtained by taking into account potential side ef-
fects related to antibiotic administration to patients who
may not have needed antibiotics, such as those suffering
from viral infections. More importantly, in clinical prac-
tice, many patients receive antibiotics while being culture-
negative, either reflecting more localized infections like a
pneumonia without bacteremia, or viral infections. These
patients should be included to assess the overall benefit of
antibiotics.
Conclusions
In our study cohort of ED patients with mild to severe
sepsis stages and overall mortality of 10%, a reduction in
time to antibiotics was not found to be associated with
an improvement in relevant clinical outcomes. Future
studies should investigate if other aspects of ED treat-
ment, especially appropriateness of initial antibiotics and
initial resuscitation with fluids and oxygen, are more im-
portant in sepsis stages preceding septic shock.
Key messages
 A reduction in time to antibiotics was not found to
be associated with an improvement in hospital
length of stay in emergency department patients
with mild to severe sepsis stages.
de Groot et al. Critical Care  (2015) 19:194 Page 11 of 12 A reduction in time to antibiotics was not found to
be associated with a reduction in 28-day mortality in
emergency department patients with mild to severe
sepsis stages.
 Future studies should investigate if other aspects of
ED treatment, especially appropriateness of initial
antibiotics and initial resuscitation with fluids and
oxygen, are more important in sepsis stages
preceding septic shock.
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